NASDAQ:ADMA ADMA Biologics (ADMA) Stock Price, News & Analysis $10.34 +0.03 (+0.29%) Closing price 04:00 PM EasternExtended Trading$10.27 -0.07 (-0.67%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ADMA Biologics Stock (NASDAQ:ADMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ADMA Biologics alerts:Sign Up Key Stats Today's Range$10.23▼$10.6050-Day Range$8.61▼$10.3652-Week Range$7.21▼$20.46Volume2.88 million shsAverage Volume3.40 million shsMarket Capitalization$2.32 billionP/E Ratio14.52Dividend YieldN/APrice Target$18.67Consensus RatingModerate Buy Company Overview ADMA Biologics, Inc. is a commercial biopharmaceutical company focused on developing, manufacturing and marketing plasma-derived biologic products for people with compromised immune systems. The company’s operations include collecting human source plasma, developing therapies from donated plasma and producing specialty immunoglobulin products. ADMA’s commercial portfolio includes BIVIGAM, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency, and ASCENIV, an intravenous immune globulin product for patients with primary immunodeficiency diseases. The company also markets Nabi-HB, a hepatitis B immune globulin used to help prevent hepatitis B infection in certain clinical situations. Headquartered in Boca Raton, Florida, ADMA serves the U.S. specialty pharmaceutical and healthcare markets through its plasma collection, manufacturing and commercial operations. The company was founded in 2004 and is led by President and Chief Executive Officer Adam S. Grossman.AI Generated. May Contain Errors. Read More ADMA Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreADMA MarketRank™: 3.90852937311 of 5 starsADMA Biologics scored higher than 78% of companies evaluated by MarketBeat, and ranked 127th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingADMA Biologics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialADMA Biologics has a consensus price target of $18.67, representing about 80.5% upside from its current price of $10.34.Amount of Analyst CoverageADMA Biologics has only been the subject of 2 research reports in the past 90 days.Read more about ADMA Biologics' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.97% Earnings GrowthEarnings for ADMA Biologics are expected to grow by 8.97% in the coming year, from $0.78 to $0.85 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ADMA Biologics is 14.77, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.75.Price to Earnings Ratio vs. SectorThe P/E ratio of ADMA Biologics is 14.77, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.31.Price to Book Value per Share RatioADMA Biologics has a P/B Ratio of 5.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ADMA Biologics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.57% of the float of ADMA Biologics has been sold short.Short Interest Ratio / Days to CoverADMA Biologics has a short interest ratio ("days to cover") of 5.67.Change versus previous monthShort interest in ADMA Biologics has recently decreased by 14.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldADMA Biologics does not currently pay a dividend.Dividend GrowthADMA Biologics does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentADMA Biologics has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for ADMA Biologics this week, compared to 8 articles on an average week.Search InterestOnly 7 people have searched for ADMA on MarketBeat in the last 30 days. This is a decrease of -61% compared to the previous 30 days.MarketBeat Follows5 people have added ADMA Biologics to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ADMA Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders3.90% of the stock of ADMA Biologics is held by insiders.Percentage Held by Institutions75.68% of the stock of ADMA Biologics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ADMA Biologics' insider trading history. Receive ADMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADMA Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADMA Stock News HeadlinesADMA Biologics Inc (NASDAQ:ADMA) Stock Has Consensus Target Price of $18.67 According to AnalystsOctober 5, 2026 | americanbankingnews.comADMA Biologics (ADMA), Why Is It Back In The Spotlight?September 27, 2026 | finance.yahoo.comElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he says is the same size Nvidia was a decade ago. The company holds 150 patents protecting its core technology, and Brown believes Elon Musk could soon drive major demand for it. A key catalyst is set for November 11.October 14 at 1:00 AM | Brownstone Research (Ad)Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)September 8, 2026 | prnewswire.comADMA Biologics: Maybe The Bears Are Right (Rating Downgrade)September 2, 2026 | seekingalpha.comBerger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)August 31, 2026 | prnewswire.comADMA Biologics, Inc. (ADMA) Stock Earnings Call Transcripts - Yahoo FinanceAugust 23, 2026 | finance.yahoo.comADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMAAugust 21, 2026 | prnewswire.comSee More Headlines ADMA Stock Analysis - Frequently Asked Questions How have ADMA shares performed this year? ADMA Biologics' stock was trading at $18.24 at the beginning of the year. Since then, ADMA stock has decreased by 43.3% and is now trading at $10.34. How were ADMA Biologics' earnings last quarter? ADMA Biologics Inc (NASDAQ:ADMA) issued its earnings results on Wednesday, August, 5th. The biotechnology company reported $0.16 EPS for the quarter, missing analysts' consensus estimates of $0.16 by $0.00. The firm's quarterly revenue was up 2.0% compared to the same quarter last year. Read the conference call transcript. When did ADMA Biologics IPO? ADMA Biologics (ADMA) raised $30 million in an initial public offering (IPO) on the week of November 10th 2014. The company issued 3,352,941 shares at a price of $8.50-$9.50 per share. Who are ADMA Biologics' major shareholders? ADMA Biologics' top institutional investors include City Center Advisors LLC (0.02%), First Citizens Bank & Trust Co. (0.01%), NorthCrest Asset Manangement LLC (0.01%) and GAMMA Investing LLC. Insiders that own company stock include Adam S Grossman, Steve Elms, Jerrold B Grossman, Kaitlin M Kestenberg-Messina, Young Kwon, Brad L Tade and Lawrence P Guiheen. View institutional ownership trends. How do I buy shares of ADMA Biologics? Shares of ADMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ADMA Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that ADMA Biologics investors own include NVIDIA (NVDA), Tesla (TSLA), Palantir Technologies (PLTR), Advanced Micro Devices (AMD), Ford Motor (F), Viking Therapeutics (VKTX) and Micron Technology (MU). Company Calendar Last Earnings8/05/2026Today10/14/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ADMA's financial health is in the Red zone, according to TradeSmith. ADMA has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ADMA CIK1368514 Webwww.admabiologics.com Phone(201) 478-5552Fax201-478-5553Employees647Year Founded2004Price Target and Rating Average Price Target for ADMA Biologics$18.67 High Price Target$21.00 Low Price Target$17.00 Potential Upside/Downside+80.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$0.70 Trailing P/E Ratio14.77 Forward P/E Ratio13.26 P/E GrowthN/ANet Income$146.93 million Net Margins32.98% Pretax Margin42.26% Return on Equity40.17% Return on Assets26.97% Debt Debt-to-Equity Ratio0.49 Current Ratio6.97 Quick Ratio3.81 Sales & Book Value Annual Sales$512.28 million Price / Sales4.52 Cash Flow$0.66 per share Price / Cash Flow15.56 Book Value$2.01 per share Price / Book5.14Miscellaneous Outstanding Shares223,985,000Free Float215,250,000Market Cap$2.32 billion OptionableOptionable Beta0.70 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ADMA) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredMy next big call (under $1)The obvious way to "bet on Trump" in crypto is the Trump memecoin. And right now it's back in the news, with a...Crypto 101 Media | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
